Merck Stock Based Compensation from 2010 to 2024

MRK Stock

USD 128.71 0.29 0.23%

Merck Stock Based Compensation yearly trend continues to be quite stable with very little volatility. The value of Stock Based Compensation is projected to decrease to about 346.8 M. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2006-03-31

Previous Quarter

167 M

Current Value

167 M

Quarterly Volatility

173.4 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 1.2 B or Total Revenue of 32.5 B, as well as many indicators such as Price To Sales Ratio of 4.3, Dividend Yield of 0.0246 or PTB Ratio of 6.91. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.

Check out the analysis of Merck Correlation against competitors.

Latest Merck's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Merck Company over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Merck's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Merck Stock Based Compensation Regression Statistics

	Arithmetic Mean	330,560,952
	Coefficient Of Variation	73.76
	Mean Deviation	130,768,762
	Median	346,814,285
	Standard Deviation	243,837,147
	Sample Variance	59456.6T
	Range	1.1B
	R-Value	0.66
	Mean Square Error	36351.2T
	R-Squared	0.43
	Significance	0.01
	Slope	35,848,214
	Total Sum of Squares	832391.8T

Merck Stock Based Compensation History

	2024	346.8 M
	2023	645 M
	2022	541 M
	2021	479 M
	2020	475 M
	2019	417 M
	2018	348 M

Other Fundumenentals of Merck Company

Stock Based Compensation To Revenue

Merck Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.87	0.28	0.88	0.61	0.7	0.98	0.3	0.8	0.49	0.16	0.95	0.95	0.73	0.65	-0.27	0.44	-0.21	-0.22	0.19	0.35	0.22	0.36	0.31	-0.7	0.02	0.19	0.2	0.15
Total Stockholder Equity	0.87		-0.07	0.59	0.43	0.4	0.9	0.08	0.93	0.05	0.37	0.72	0.72	0.36	0.22	0.18	0.21	-0.26	0.23	-0.07	-0.02	0.1	0.61	0.48	-0.48	-0.37	-0.07	0.16	0.35
Net Debt	0.28	-0.07		0.57	0.75	0.83	0.18	0.11	-0.09	0.73	-0.2	0.42	0.42	0.74	0.71	-0.89	0.5	0.52	-0.58	0.54	0.82	0.58	-0.42	-0.26	-0.43	0.32	0.56	0.48	-0.1
Retained Earnings	0.88	0.59	0.57		0.69	0.83	0.84	0.26	0.5	0.8	0.01	0.9	0.9	0.91	0.89	-0.65	0.58	0.03	-0.48	0.37	0.65	0.37	0.04	0.04	-0.74	0.24	0.48	0.37	0.18
Net Receivables	0.61	0.43	0.75	0.69		0.91	0.57	0.13	0.47	0.6	-0.28	0.63	0.63	0.68	0.57	-0.63	0.71	0.5	-0.35	0.51	0.6	0.68	0.08	-0.26	-0.59	0.01	0.58	0.6	0.16
Total Liab	0.7	0.4	0.83	0.83	0.91		0.64	0.35	0.4	0.75	-0.17	0.78	0.78	0.81	0.78	-0.77	0.56	0.25	-0.59	0.52	0.65	0.45	-0.05	-0.09	-0.75	0.28	0.46	0.38	-0.03
Total Current Assets	0.98	0.9	0.18	0.84	0.57	0.64		0.31	0.82	0.4	0.21	0.91	0.91	0.64	0.55	-0.18	0.4	-0.25	-0.12	0.15	0.24	0.18	0.38	0.33	-0.71	-0.06	0.18	0.16	0.19
Short Term Debt	0.3	0.08	0.11	0.26	0.13	0.35	0.31		0.12	0.3	-0.27	0.41	0.41	0.13	0.26	-0.22	0.03	-0.44	-0.47	0.19	-0.13	-0.35	-0.04	0.1	-0.63	0.73	-0.13	-0.43	-0.63
Intangible Assets	0.8	0.93	-0.09	0.5	0.47	0.4	0.82	0.12		0.07	0.15	0.65	0.65	0.29	0.16	0.19	0.28	-0.21	0.14	-0.05	-0.05	0.11	0.75	0.25	-0.47	-0.31	-0.09	0.14	0.22
Accounts Payable	0.49	0.05	0.73	0.8	0.6	0.75	0.4	0.3	0.07		-0.37	0.58	0.58	0.85	0.9	-0.9	0.63	0.25	-0.75	0.44	0.8	0.38	-0.33	-0.39	-0.65	0.57	0.58	0.39	-0.09
Short Term Investments	0.16	0.37	-0.2	0.01	-0.28	-0.17	0.21	-0.27	0.15	-0.37		0.14	0.14	-0.11	-0.14	0.39	-0.55	-0.48	0.36	-0.28	-0.27	-0.35	0.22	0.77	0.11	-0.4	-0.48	-0.3	0.08
Capital Stock	0.95	0.72	0.42	0.9	0.63	0.78	0.91	0.41	0.65	0.58	0.14		1.0	0.77	0.76	-0.42	0.38	-0.27	-0.43	0.3	0.38	0.19	0.24	0.29	-0.7	0.21	0.23	0.06	-0.03
Common Stock	0.95	0.72	0.42	0.9	0.63	0.78	0.91	0.41	0.65	0.58	0.14	1.0		0.77	0.76	-0.42	0.38	-0.27	-0.43	0.3	0.38	0.19	0.24	0.29	-0.7	0.21	0.23	0.06	-0.03
Long Term Debt	0.73	0.36	0.74	0.91	0.68	0.81	0.64	0.13	0.29	0.85	-0.11	0.77	0.77		0.93	-0.76	0.67	0.23	-0.52	0.41	0.88	0.56	-0.2	-0.09	-0.58	0.24	0.6	0.49	0.11
Good Will	0.65	0.22	0.71	0.89	0.57	0.78	0.55	0.26	0.16	0.9	-0.14	0.76	0.76	0.93		-0.83	0.51	0.07	-0.75	0.5	0.79	0.33	-0.2	-0.1	-0.56	0.49	0.51	0.28	-0.02
Treasury Stock	-0.27	0.18	-0.89	-0.65	-0.63	-0.77	-0.18	-0.22	0.19	-0.9	0.39	-0.42	-0.42	-0.76	-0.83		-0.55	-0.44	0.77	-0.56	-0.83	-0.46	0.51	0.43	0.51	-0.54	-0.67	-0.4	0.07
Property Plant Equipment	0.44	0.21	0.5	0.58	0.71	0.56	0.4	0.03	0.28	0.63	-0.55	0.38	0.38	0.67	0.51	-0.55		0.61	-0.23	0.39	0.71	0.84	-0.05	-0.6	-0.41	0.04	0.85	0.75	0.24
Current Deferred Revenue	-0.21	-0.26	0.52	0.03	0.5	0.25	-0.25	-0.44	-0.21	0.25	-0.48	-0.27	-0.27	0.23	0.07	-0.44	0.61		0.07	0.28	0.58	0.81	-0.33	-0.65	0.07	-0.25	0.66	0.85	0.43
Net Tangible Assets	-0.22	0.23	-0.58	-0.48	-0.35	-0.59	-0.12	-0.47	0.14	-0.75	0.36	-0.43	-0.43	-0.52	-0.75	0.77	-0.23	0.07		-0.51	-0.46	0.02	0.23	0.33	0.4	-0.82	-0.31	0.14	0.45
Total Permanent Equity	0.19	-0.07	0.54	0.37	0.51	0.52	0.15	0.19	-0.05	0.44	-0.28	0.3	0.3	0.41	0.5	-0.56	0.39	0.28	-0.51		0.43	0.31	0.0	-0.35	-0.3	0.25	0.41	0.25	-0.04
Long Term Debt Total	0.35	-0.02	0.82	0.65	0.6	0.65	0.24	-0.13	-0.05	0.8	-0.27	0.38	0.38	0.88	0.79	-0.83	0.71	0.58	-0.46	0.43		0.72	-0.42	-0.38	-0.31	0.18	0.74	0.69	0.18
Capital Surpluse	0.22	0.1	0.58	0.37	0.68	0.45	0.18	-0.35	0.11	0.38	-0.35	0.19	0.19	0.56	0.33	-0.46	0.84	0.81	0.02	0.31	0.72		-0.14	-0.47	-0.08	-0.29	0.82	0.84	0.39
Deferred Long Term Liab	0.36	0.61	-0.42	0.04	0.08	-0.05	0.38	-0.04	0.75	-0.33	0.22	0.24	0.24	-0.2	-0.2	0.51	-0.05	-0.33	0.23	0.0	-0.42	-0.14		0.15	0.01	-0.33	-0.33	-0.14	0.08
Long Term Investments	0.31	0.48	-0.26	0.04	-0.26	-0.09	0.33	0.1	0.25	-0.39	0.77	0.29	0.29	-0.09	-0.1	0.43	-0.6	-0.65	0.33	-0.35	-0.38	-0.47	0.15		-0.03	-0.22	-0.6	-0.43	0.01
Accumulated Depreciation	-0.7	-0.48	-0.43	-0.74	-0.59	-0.75	-0.71	-0.63	-0.47	-0.65	0.11	-0.7	-0.7	-0.58	-0.56	0.51	-0.41	0.07	0.4	-0.3	-0.31	-0.08	0.01	-0.03		-0.35	-0.17	-0.15	0.12
Short Long Term Debt	0.02	-0.37	0.32	0.24	0.01	0.28	-0.06	0.73	-0.31	0.57	-0.4	0.21	0.21	0.24	0.49	-0.54	0.04	-0.25	-0.82	0.25	0.18	-0.29	-0.33	-0.22	-0.35		0.07	-0.34	-0.65
Cash And Equivalents	0.19	-0.07	0.56	0.48	0.58	0.46	0.18	-0.13	-0.09	0.58	-0.48	0.23	0.23	0.6	0.51	-0.67	0.85	0.66	-0.31	0.41	0.74	0.82	-0.33	-0.6	-0.17	0.07		0.67	0.34
Net Invested Capital	0.2	0.16	0.48	0.37	0.6	0.38	0.16	-0.43	0.14	0.39	-0.3	0.06	0.06	0.49	0.28	-0.4	0.75	0.85	0.14	0.25	0.69	0.84	-0.14	-0.43	-0.15	-0.34	0.67		0.64
Net Working Capital	0.15	0.35	-0.1	0.18	0.16	-0.03	0.19	-0.63	0.22	-0.09	0.08	-0.03	-0.03	0.11	-0.02	0.07	0.24	0.43	0.45	-0.04	0.18	0.39	0.08	0.01	0.12	-0.65	0.34	0.64

Click cells to compare fundamentals

About Merck Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Merck income statement, its balance sheet, and the statement of cash flows. Merck investors use historical funamental indicators, such as Merck's Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Merck investors may use each financial statement separately, they are all related. The changes in Merck's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Merck's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Merck Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Merck. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	645 M	346.8 M
Stock Based Compensation To Revenue	0.01	0.01

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Merck Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

Additional Information and Resources on Investing in Merck Stock

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Merck Correlation against competitors.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.685

Dividend Share

2.96

Earnings Share

0.9

Revenue Per Share

24.215

Quarterly Revenue Growth

0.089

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Stock Based Compensation from 2010 to 2024

Latest Merck's Stock Based Compensation Growth Pattern

Merck Stock Based Compensation Regression Statistics

Merck Stock Based Compensation History

Other Fundumenentals of Merck Company

Merck Stock Based Compensation component correlations

About Merck Financial Statements

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Additional Information and Resources on Investing in Merck Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY